Mackenzie Financial’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $43.2M | Buy |
96,709
+33,410
| +53% | +$15.6M | 0.05% | 281 |
|
|
2025
Q4 | $28.7M | Buy |
63,299
+8,956
| +16% | +$3.86M | 0.03% | 334 |
|
|
2025
Q3 | $21.3M | Buy |
54,343
+18,068
| +50% | +$7.55M | 0.03% | 370 |
|
|
2025
Q2 | $16.1M | Buy |
36,275
+209
| +0.6% | +$96.3K | 0.02% | 404 |
|
|
2025
Q1 | $17.5M | Sell |
36,066
-9,566
| -21% | -$4.46M | 0.02% | 366 |
|
|
2024
Q4 | $18.4M | Sell |
45,632
-23,060
| -34% | -$10.7M | 0.03% | 365 |
|
|
2024
Q3 | $31.9M | Sell |
68,692
-15,942
| -19% | -$7.66M | 0.04% | 278 |
|
|
2024
Q2 | $39.7M | Sell |
84,634
-7,818
| -8% | -$3.39M | 0.06% | 244 |
|
|
2024
Q1 | $38.6M | Buy |
92,452
+5,625
| +6% | +$2.38M | 0.06% | 246 |
|
|
2023
Q4 | $35.3M | Buy |
86,827
+3,856
| +5% | +$1.42M | 0.05% | 252 |
|
|
2023
Q3 | $28.6M | Sell |
82,971
-9,719
| -10% | -$3.4M | 0.05% | 264 |
|
|
2023
Q2 | $32.2M | Sell |
92,690
-118,393
| -56% | -$39.9M | 0.05% | 259 |
|
|
2023
Q1 | $66.5M | Buy |
211,083
+102,181
| +94% | +$30.6M | 0.1% | 182 |
|
|
2022
Q4 | $31.4M | Sell |
108,902
-9,220
| -8% | -$2.81M | 0.05% | 261 |
|
|
2022
Q3 | $34.2M | Buy |
118,122
+28,080
| +31% | +$8.08M | 0.06% | 248 |
|
|
2022
Q2 | $25.4M | Sell |
90,042
-9,283
| -9% | -$2.48M | 0.04% | 288 |
|
|
2022
Q1 | $25.9M | Buy |
99,325
+11,876
| +14% | +$2.82M | 0.03% | 308 |
|
|
2021
Q4 | $19.2M | Buy |
87,449
+1,896
| +2% | +$369K | 0.03% | 376 |
|
|
2021
Q3 | $15.5M | Buy |
85,553
+4,503
| +6% | +$879K | 0.02% | 391 |
|
|
2021
Q2 | $16.3M | Buy |
81,050
+10,827
| +15% | +$2.26M | 0.02% | 367 |
|
|
2021
Q1 | $15.1M | Buy |
70,223
+32,402
| +86% | +$7.12M | 0.02% | 358 |
|
|
2020
Q4 | $8.94M | Buy |
37,821
+13,435
| +55% | +$3.08M | 0.02% | 359 |
|
|
2020
Q3 | $6.64M | Buy |
24,386
+7,080
| +41% | +$1.95M | 0.02% | 363 |
|
|
2020
Q2 | $5.02M | Buy |
17,306
+7,852
| +83% | +$2.13M | 0.01% | 398 |
|
|
2020
Q1 | $2.25M | Buy |
9,454
+5,281
| +127% | +$1.21M | 0.01% | 480 |
|
|
2019
Q4 | $914K | Buy |
4,173
+2,666
| +177% | +$540K | ﹤0.01% | 747 |
|
|
2019
Q3 | $255K | Buy |
1,507
+9
| +0.6% | +$1.59K | ﹤0.01% | 920 |
|
|
2019
Q2 | $275K | Sell |
1,498
-29,512
| -95% | -$5.16M | ﹤0.01% | 976 |
|
|
2019
Q1 | $5.7M | Sell |
31,010
-39,700
| -56% | -$7.33M | 0.01% | 488 |
|
|
2018
Q4 | $11.7M | Buy |
70,710
+65,561
| +1,273% | +$11.4M | 0.03% | 335 |
|
|
2018
Q3 | $992K | Buy |
5,149
+143
| +3% | +$25.5K | ﹤0.01% | 758 |
|
|
2018
Q2 | $851K | Buy |
5,006
+991
| +25% | +$154K | ﹤0.01% | 702 |
|
|
2018
Q1 | $654K | Buy |
4,015
+1,775
| +79% | +$290K | ﹤0.01% | 692 |
|
|
2017
Q4 | $336K | Buy |
+2,240
| New | +$332K | ﹤0.01% | 743 |
|
|
2016
Q4 | – | Sell |
-13,697
| Closed | -$1.2M | – | 737 |
|
|
2016
Q3 | $1.2M | Sell |
13,697
-108,410
| -89% | -$10.2M | 0.01% | 395 |
|
|
2016
Q2 | $10.5M | Buy |
122,107
+6,156
| +5% | +$532K | 0.06% | 248 |
|
|
2016
Q1 | $9.22M | Buy |
115,951
+42,683
| +58% | +$3.86M | 0.08% | 211 |
|
|
2015
Q4 | $9.22M | Buy |
73,268
+5,300
| +8% | +$640K | 0.06% | 252 |
|
|
2015
Q3 | $7.08M | Buy |
67,968
+64,768
| +2,024% | +$8.32M | 0.04% | 267 |
|
|
2015
Q2 | $395K | Sell |
3,200
-1,200
| -27% | -$151K | ﹤0.01% | 710 |
|
|
2015
Q1 | $519K | Buy |
4,400
+600
| +16% | +$71.9K | ﹤0.01% | 654 |
|
|
2014
Q4 | $451K | Sell |
3,800
-6,600
| -63% | -$743K | ﹤0.01% | 649 |
|
|
2014
Q3 | $1.17M | Buy |
+10,400
| New | +$990K | 0.01% | 486 |
|
|
2013
Q3 | – | Sell |
-15,300
| Closed | -$1.23M | – | 666 |
|
|
2013
Q2 | $1.23M | Buy |
+15,300
| New | +$1.13M | 0.01% | 460 |
|
Other funds holding VRTX
VCM
VPM
Mackenzie Financial's VRTX Position: Q1 2026 in Review
Mackenzie Financial increased its Vertex Pharmaceuticals (VRTX) stake by 53% in Q1 2026, buying an estimated $15.6M and bringing the position to 96,709 shares worth $43.2M. The position accounts for 0.05% of the portfolio, ranked #281.
Mackenzie Financial first reported a position in VRTX in Q2 2013 and has held it in 44 quarters since. The position peaked at $66.5M in Q1 2023. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Mackenzie Financial held 96,709 shares of Vertex Pharmaceuticals worth $43.2M as of Q1 2026.
- Mackenzie Financial bought 33,410 Vertex Pharmaceuticals shares in Q1 2026, an estimated $15.6M.
- Vertex Pharmaceuticals made up 0.05% of Mackenzie Financial's portfolio in Q1 2026, its #281 holding.
- Mackenzie Financial first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 44 quarters since.
- Mackenzie Financial's Vertex Pharmaceuticals position peaked at $66.5M in Q1 2023.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Mackenzie Financial's 13F filing for Q1 2026, filed 13 May 2026.